Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.

Inclusion Criteria

Patient has provided written informed consent
Patient is an adult (≥ 18 years of age at the time of informed consent) with a diagnosis of melanoma
Patient enrolled within 1 month of receiving the first dose of IMLYGIC for the treatment of melanoma

Exclusion Criteria

Patient has a prior history of being a subject in an interventional clinical trial for IMLYGIC

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02910557.

Trial PhaseNo phase specified

Trial TypeNot provided by clinicaltrials.gov

Lead OrganizationAmgen, Inc.

Primary ID20130193
Secondary IDsNCI-2019-06388
ClinicalTrials.gov IDNCT02910557

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

Inclusion Criteria

Exclusion Criteria

Have a question?
We're here to help

Which trials are right for you?

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help